Loading
A phase 3 trial of Zanidatamab, Trastuzumab, Eribulin in her2-positive breast cancer, run by Jazz Pharmaceuticals, now recruiting.
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer is a phase 3 interventional study registered as NCT06435429 by Jazz Pharmaceuticals, with 550 participants planned, started 2024-08-13 and due to reach its primary completion in 2028-04-28. Interventions recorded: Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine. Conditions listed: Metastatic HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Vinorelbine, Eribulin, Trastuzumab, Capecitabine.
Shares Jazz Pharmaceuticals, Zanidatamab, Bispecific antibodies, Trastuzumab.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine.
Shares Eribulin, Capecitabine, Gemcitabine, HER2-positive breast cancer.
Shares Vinorelbine, Eribulin, Capecitabine, Gemcitabine.
Shares Vinorelbine, Eribulin, Trastuzumab, Capecitabine.
Shares Trastuzumab, Capecitabine, Gemcitabine, HER2-positive breast cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/